Given the increasing evidence for a potent role of YAP/TAZ in malignant tumours, future work should examine whether the Hippo pathway might be the primary effector of PI3K–Akt signalling in human cancer and thus a critical target for therapy. This evidence concerns the gene YAP1 and neoplasm.